Key words Rheumatoid arthritis, tuberculosis, high-resolution computerized tomography, chest x-ray, purified protein derivative (PPD) test.
|
- Stuart Blake
- 11 days ago
- Views:
Transcription
1 A low prevalance of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings İ.H. Köker 1, Ö.N. Pamuk 2, C. Karlikaya 3, N. Tunçbilek 4, N. Çakir 2 1 Department of Internal Medicine, 2 Department of Rheumatology, 3 Department of Chest Diseases and 4 Department of Radiodiagnostics, Trakya Medical Faculty, University of Trakya, Edirne, Turkey. Abstract Objectives In this study, we aimed to evaluate the frequency of purified protein derivative (PPD) skin test positivity and associated clinical features in RA patients. Materials and methods We included 94 (80 F, 14 M, mean age: 55.8) consecutive RA patients with a disease duration of 8.7 years. PPD test was performed in all RA patients; clinical features were recorded down; chest x-ray, pulmonary function tests and HRCT were available in all cases. As the control group, we included data of 21 SLE, 44 AS, 27 OA, 16 gouty arthritis and 18 vasculitis patients. Results The frequencies of PPD positivity in RA (29.8%) and SLE (19%) patients were lower than in patients with AS (65.9%), gouty arthritis (68.8%) and OA (63%) (all p values < 0.01). PPD-positive RA patients were more frequently smokers (p = 0.005) and had a higher rate of RF seropositivity (p = 0.04) than PPD-negatives. PPD was less frequently positive in erosive RA disease (p = 0.033). Chest x-rays and HRCT abnormalities were detected in 41.8% and 62.7% of RA patients, respectively. Frequencies of chest x-ray and HRCT abnormalities in PPD-positive and PPD-negative patients were not different from each other (p > 0.05). Conclusion In our country in which tuberculosis is relatively frequent -contrary to the situation in AS patients- we observed a lower frequency of PPD positivity in RA and SLE patients compared to patients with other rheumatic diseases. We did not find any relationship between PPD positivity and the frequency of chest x-ray, HRCT abnormalities. Key words Rheumatoid arthritis, tuberculosis, high-resolution computerized tomography, chest x-ray, purified protein derivative (PPD) test. Clinical and Experimental Rheumatology 2007; 25: 54-59
2 Ibrahim Hakki Köker, Ömer Nuri Pamuk, MD; Celal Karlikaya, MD, Professor in Medicine; Nermin Tunçbilek, MD, Associated Professor in Medicine; Necati Çakir, MD, Professor in Medicine. Please address correspondence and reprint requests to: Dr. Necati Çakır, Altunizade, Okul Sokak, Erzurum Sitesi, No: 25 Daire: 2, Üsküdar, 22030, Istanbul, Turkey. Received on February 22, 2006; accepted in revised form on July 27, Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Introduction Pleuroparenchymal complications are one of the important factors leading to the increased morbidity and mortality in rheumatoid arthritis (RA) (1). These complications are mainly observed in patients with severe chronic articular disease who are seropositive, and who have other extraarticular findings (2). The usage of TNF-blockers in the treatment of RA in recent years and the increased incidence of infections - especially tuberculosis (TB) - with these drugs make it obligatory to interpret the pulmonary findings and purified protein derivative (PPD) skin test (3, 4). PPD is currently the only method which detects latent TB (5). Nevertheless, there is a defect in cellular immunity in RA and patientsʼ response to PPD test might not be sufficient (6). Chest x-ray is an easy and cheap method; however, its sensitivity is relatively low, and the presence of sequela findings might pose problems. High-resolution CT (HRCT) is quite a sensitive method to detect pulmonary pathologies. After the usage of HRCT became more common, the association of many lesions that could not be detected on routine x- rays with RA have been defined. In our study, we determined the frequency of pulmonary involvement in our RA patients and compared the results of various diagnostic methods. Chest x-rays were interpreted; pulmonary function tests (PFT), HRCT, and PPD were obtained and their relationship with the clinical features of RA was determined. Materials and methods Ninety-four (80 females, 14 males, mean age: 55.8 ± 12) consecutive RA patients followed up at the Division of Rheumatology, Trakya University Medical Faculty were included in the study. RA patients were diagnosed according to ACR 1987 criteria (7). Patients with nonspecific immunosuppression (chronic hepatic and renal diseases, diabetes, or malignant diseases) and known chronic obstructive pulmonary disease, cardiac failure, pneumoconiosis were excluded. The study was approved by the ethical committee of A comparative study / İ.H. Köker et al. our center. All patients were given detailed information and written consent was obtained from each patient. Data about age, sex, disease duration, medical treatment and drug history, extraarticular manifestations and other diseases of RA patients were recorded down from the hospital files. All RA patients and controls were questionned about history of smoking and pulmonary symptoms. RA patients underwent detailed joint and respiratory system examination. In addition, blood samples were drawn from RA patients for ESR, CRP, rheumatoid factor (RF), and whole blood count. DAS28 was estimated and patients were grouped as active or inactive. Active disease was defined as DAS28 score more than 3.1 (8). Hand x-rays of all patients were available. All RA patients had chest x-rays. HRCT was performed in 67 RA patients (Toshiba TCT 300S Scanner). The sections were 2 mm-thick and obtained at 20 mm-intervals starting from apices of the lungs till the bases of the costophrenic sinuses. The sections were recorded at end-inspiratory volume the scanning time of which is 1 second. The images were reconstructed with high spatial frequency algorithm for parenchymal evaluation and with standard algorithm for mediastinal evaluation. HRCT findings were divided into the following as; bronchiectasis, bronchial wall thickening, nodule, emphysema, pleural thickening/calcification, pleural effusion, septal thickening/parenchymal bands, ground-glass and honeycomb appearance. The classification of typical findings of reactivated pulmonary TB were according to a previous report (9). Typical findings for TB included centrilobular nodules, tree in bud appearance, a single cavitary nodule and acinar or lobular nodule. All chest x-rays were interpreted at two different time periods by one radiologist (NT) an one pneumologist (CK) who were blind to one another and also to the clinical features of the patients. The intraobserver agreement for chest x-rays was excellent (kappa = 0.81 and 0.90); interobserver agreement was good (kappa = 0.62). All 55
3 A comparative study / İ.H. Köker et al. HRCT scans were interpreted at two different time periods by one radiologist (NT). The intraobserver concordance of chest x-ray evaluations was good (kappa = 0.63). The PFT of the patient and the control groups were determined by computerized spirometry (Sensor Medics, V- max 22, Yorbolinda, CA). PFT included forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), and the diffusing capacity for carbon monoxide (DLCO) using the single breath technique and corrected for lung volume and hemoglobin levels. The results were expressed as a percentage of the predicted value compared with individuals of similar sex, age, weight and height. PPD was performed using the Mantoux method (5) and was measured 48 to 72 hours later. PPD was considered positive if the induration was 5 mm. The PPD test was performed simultaneously with the HRCT. We routinely apply PPD test to all patients who are admitted to our department because the frequency of TB in our country is high. In addition, as a control group, we retrospectively evaluated PPD results of 21 systemic lupus erythematosus (SLE), 44 ankylosing spondylitis (AS), 16 gouty arthritis, 27 osteoarthritis (OA), and 18 vasculitis patients who were admitted to our department with-in the last 4 years. All SLE patients fulfilled the revised ACR criteria (10), all AS patients fulfilled modified New York classification criteria (11), gouty arthritis patients met the American Rheumatology Association diagnostic criteria for acute gout (12), and OA patients fulfilled the ACR criteria (13). Chi-square test was used to compare categoric variables, and to determine intraobserver and interobserver agreement; and concordance coefficient, kappa, was calculated. In the comparison of quantitative variables, Mann-Whitney U test was used. Results The mean disease duration in RA patients was 8.7 years (10.2), RF was positive in 55.3%, 66% had erosive disease. Fifty percent of RA patients were using at least one DMARD, 36.2% methotrexate, 22.3% sulphasalazine, 14.9% antimalarial drugs, and 50% were using steroids. In 17.2% of RA patients, FEV1 and FVC; in 52.5%, FEF25-75; and in 45.8%, DLCO were low. The clinical and demographic features, and results of PPD skin tests of RA patients and other groups are seen in Table I. Mean ages of AS and SLE patients were significantly lower than the other groups (all p values < 0.01). The mean age of gouty arthritis patients was significantly higher than RA and OA patients (p values 0.05). The frequency of PPD positivity in RA patients (29.8%) was significantly lower than in AS (65.9%), gouty arthritis (68.8%) and OA (63%) patients (all p values < 0.01). The frequency of PPD positivity in SLE patients (19%) was significantly lower than in AS, gouty arthritis and OA patients (all p values < 0.01). The frequency of PPD positivity in vasculitis group was lower than in gouty arthritis and AS groups (p < 0.05). Fifty-two RA patients (55.3%) had no reaction to PPD (0 mm) compared with 12 (27.3%) AS patients (p = 0.002). In addition, the mean size of the PPD induration in patients with RA and SLE were significantly less than those in AS and gouty arthritis patients (p values < 0.01). When clinical features of PPD-positive RA patients were compared to PPDnegative patients, it was observed that PPD positivity was more frequent in smoking patients (39.3% vs. 13.6%, p = 0.005) and in seropositives (71.4% vs. 48.5%, p = 0.04). PPD was less frequently positive in erosive RA disease (50% vs. 72.7%, p = 0.033). Mean hemoglobin level was higher in PPD-positive RA patients than in the PPD-negative group (p = 0.026). RA patients with a positive PPD were similar to others in ESR, CRP, disease duration, DMARD and steroid intake, and PFT. Clinical features of PPD-positive and negative patients are seen in Table II. The frequency of pathologic chest x- rays in RA patients was 41.8%. Abnormalities on HRCT were recorded in 42 (62.7%) RA patients. Agreement between HRCT and chest x-ray results was 71.1% (kappa = 0.43). The lesions detected on HRCT were septal thickening/parenchymal bands (25 cases, 37.3%), pleural thickening (18 cases, 26.9%), bronchiectasis (15 cases, 22.4%), pulmonary nodules (12 cases, 17.9%), pleural effusion (6 cases, 9%), bronchial wall thickness (5 cases, 7.5%), emphysema (4 cases, 6%). In addition, 5 subjects had ground-glass (7.5%), and 3 (4.5%) had honeycomb appearance. None of the patients had HRCT lesions typical for TB. The pulmonary nodules did not have typical features for TB. When the clinical features of patients who had HRCT abnormalities were compared to others, it was observed that their mean age (p = 0.002) was higher, and duration of RA (p = 0.03) was longer. It was observed that the probability of detecting pulmonary lesions on HRCT was affected significantly by the pre-sence of pulmonary symptoms (p = 0.023), and the presence of chest x-ray abnormalities (p < 0.001). Table I. The clinical features of patients with various rheumatic diseases and results of PPD test. n Age Steroid usage PPD positivity PPD (F/M) (mean SD) n (%) n (%) (mm) RA 94 (80/14) 55.8 ± (50) 28 (29.8) 4.46 ± 6.9 SLE 21 (19/2) 37.6 ± (47.6) 4 (19) 2.9 ± 6.2 AS 44 (13/31) 36.3 ± (4.5) 29 (65.9) 9.8 ± 8 Gouty arthritis 16 (5/11) 68.2 ± (68.8) 11 ± 9.8 Vasculitis 18 (6/12) 54.6 ± (77.8) 6 (33.3) 4.1 ± 5.4 Osteoarthritis 27 (13/14) 50.9 ± (14.8) 17 (63) 7.8 ±
4 A comparative study / İ.H. Köker et al. Table II. The clinical features of our RA patients who are PPD-positive and PPD-negative. Clinical features PPD (+) RA patients PPD (-) RA patients p n (%) 28 (29.8) 66 (70.2) NS Female, n (%) 22 (78.6) 58 (87.9) NS Age (years) 52.8 ± ± 12 NS RA duration (years) 7.9 ± ± 0.6 NS Active disease, n (%) 16 (57.1) 44 (66.7) NS Erosive disease, n (%) 14 (50) 48 (72.7) RF positivity, n (%) 20 (71.4) 32 (48.5) 0.04 ESR (mm/h) 60.3 ± ± 36.9 NS CRP (mg/dl) 4.03 ± ± 2.2 NS Hemoglobin (g/dl) 11.7 ± ± Smoking, n (%) 11 (39.3) 9 (13.6) DMARD usage, n (%) 14 (50) 33 (50) NS MTX usage, n (%) 10 (35.7) 24 (36.4) NS Sulphasalazine usage, n (%) 6 (21.4) 15 (22.7) NS Antimalarial usage, n (%) 4 (14.3) 10 (15.2) NS Leflunomide usage, n (%) 2 (7.1) 1 (1.5) NS Steroid usage, n (%) 13 (46.4) 34 (51.5) NS Pulmonary symptoms, n (%) 3 (10.7) 12 (18.2) NS TB history, n (%) 4 (14.3) 3 (4.5) NS FEV1 (% predicted) 95 ± ± 22.9 NS FVC (% predicted) 97.1 ± ± 19 NS DLCO (% predicted) 86.9 ± ± 2.9 NS NS: not significant. The frequencies of chest x-ray (46.7% vs. 33.3%) and HRCT abnormalities (66.7% vs. 58.5%) in PPD-positive and PPD-negative patients were not different from each other (p > 0.05). The frequencies of TB history were similar in patients with and without HRCT abnormalities (10% vs. 7.4%). PPD test was more frequently positive in patients with pleural thickening on HRCT (58.3 vs. 24.4%, p = 0.038). One of the patients who was PPD positive had thickening of the bronchial wall and findings of segmental consolidation on HRCT. In this patient, bronchoscopy was undertaken; caseification necrosis was observed in histopathologic examination; and his pulmonary lesion disappeared after anti- TB therapy. In another PPD negative patient with mild renal insufficiency due to secondary amyloidosis, miliary TB and renal failure developed three months after adalimubab therapy. This patient was not on TB prophylaxis and she died. There was ground glass appearance on her initial HRCT. Discussion TNF-blockers have recently come into use in RA and they are quite effective. The most important risks of these drugs are the development of infection and TB reactivation (3, 4, 14). Therefore, it is important to determine RA patients who will have increased risk of TB after the administration of TNF-blockers. The employment of TNF-blockers in PPD positive RA patients is of increasing relevance (15,16). Guidelines suggest that PPD test should be performed and a chest x-ray should be evaluated before tharapy in RA patients, and they advise prophylactic INH usage in the presence of a positive test and/or a suspected chest x-ray (4). In Spain, the risk of TB in RA patients was found to be increased 4-fold when compared to the general population (14). Although there is no definite data from Turkey, it is known that the prevalance of TB in Turkey is high (0.38%, unpublished data from the Ministry of Health, 1992). We diagnosed abnormalities on chest x-ray in 41.8% of RA patients. Various studies reported a frequency of % for chest x-ray abnormalities in RA (17,18). One study from Turkey stated that the frequency of abnormalities on chest x-ray in RA patients was 22.5% (19). In addition, we detected pulmonary abnormalities on HRCT in 62.7% of our RA patients. The abovementioned study from our country (19) found a prevalance of pulmonary lesions (57.5%) similar to ours. Some series reported HRCT abnormalities reaching up to 90% (17, 20). These percentages are quite high when compared to the percentages of chest x-ray abnormalities reported in previous studies. In our study, there were fewer patients with pulmonary symptoms than patients with HRCT abnormalities. This might be explained by most HRCT lesions not being serious enough to cause symptoms. We found that RA patients with HRCT abnormalities were older, had longer disease duration, more frequent pulmonary symptoms at initial presentation, erosive disease, and chest x-ray abnormalities were more frequent in these patients. Although we found a high prevalance of chest x-ray and HRCT abnormalities in RA, PPD test was less frequently positive. This condition is important as one Spanish study reported that PPD was negative in patients who developed TB after TNF-blocker usage (14). Recently, one study from Peru (21), which is a country with a high prevalance of TB similar to ours, stated that RA patients had a lower frequency of PPD positivity than controls (29% vs. 71%). Nevertheless, contrary to this, one study from USA (22) which has a low prevalance of TB reported that the frequency of PPD positivity (9.2%) was not lower in RA. We might, therefore, say that PPD might be positive less frequently than expected in RA; however, when chest x-rays are evaluated 57
5 A comparative study / İ.H. Köker et al. pulmonary pathologies are diagnosed in more patients. In Turkey, BCG vaccination is applied to everyone shortly after birth. Therefore, one factor which affects PPD results might be the BCG. This might partly explain why AS patients who are younger have a higher frequency of PPD positivity than RA patients. It is suggested that BCG might affect PPD test for up to 15 years. Nevertheless, OA patients who are similar in age to RA patients and gouty arthritis patients who are older than RA patients have high frequencies of PPD positivity; this excludes the above-mentioned probability. In addition to cellular immune dysfunction, another factor which might explain the increased frequency of PPD negativity in RA might be the usage of steroids and immunosuppressives. Nevertheless, the frequencies of steroid, methotrexate usage in PPD-positive and PPD-negative RA patients were similar. Besides, it was reported that steroid intake of less than 15 mg/day did not affect tuberculin reactivity (23). It was interesting that smoking and seropositive RA patients had higher frequencies of PPD positivity; however, positivity in the erosive group was significantly lower. HRCT and chest x-ray abnormalities were not different between PPD-positive and PPD-negative RA patients; never-theless, patients with pleural thickening on HRCT had more frequent PPD positivity. In our study, we did not search for specific antibodies anti-mycobacterium and we did not investigate the presence of M. tuberculosis in organic fluids. We diagnosed active TB in one PPD positive patient who had HRCT abnormalities. Although we do not have followup data of all patients; interestingly one PPD negative patient with ground glass appearance on HRCT developed miliary TB. When we consider data from the above-mentioned Spanish study (14), we might conclude that the PPD test might be unreliable to decide whether TB prophylaxis will be administered to RA patients who are planned to be put on TNF-blocker therapy. One of our important results was that the frequency of PPD positivity was increased in AS which is a disease in which TNF-blockers are used commonly. SLE patients had quite a lower frequency of PPD positivity than others; and, probably steroid intake by most subjects have contributed to this result. In Turkey, which is a country with a relatively high prevalance of TB, we found a low frequency of PPD positivity in RA (29.8%) and a high frequency (65.9%) in AS. Consequently when we consider data from Peru and Spain, when using TNF-blockers in areas where the frequency of disease is high - contrary to AS - the decision for prophylaxis in RA should not be based upon only PPD results. In addition, we observed that RA patients had a high frequency of abnormalities in chest x-ray and HRCT; nevertheless, these generally did not have any clinical significance and had no relationship with PPD results. Consequently, it might be wise to perform HRCT in patients with a negative PPD and a suspect chest x- ray lesion in order to decide on longterm prophylaxis. Our RA patients had no typical findings for TB on HRCT and these findings generally had no association with PPD results. Therefore, we cannot comment on the effective utility of performing an HRCT along with a PPD test. References 1. TANOUE LT: Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19: ANAYA JM, DIETHELM L, ORTIZ LA et al.: Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: HAMILTON CD: Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 2003; 48: IMPERATO AK, SMILES S, ABRAMSON SB: Long-term risks associated with biologic response modifiers used in rheumatic dis eases. Curr Opin Rheumatol 2004; 16: AMERICAN THORACIC SOCIETY: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am Resp Crit Care Med 2000; 161: PANAYI G, CORRIGALL V, PITZALIS C: Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: ARNETT FC, EDWORTHY SM, BLOCH DA et al.: American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: PREVOO ML, VANʼT HOF M, KUPER HH, VAN LEEWUEN M, VAN DE PUTTE L, VAN RIEL P: Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: IKEZOE J, TAKEUCHI N, JOHKOH T et al.: CT appearance of pulmonary tuberculosis in diabetic and immunocompromised patients. Comparison with patients who had no underlying disease. AJR Am J Roentgenol 1992; 159: TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: WALLACE SL, ROBINSON H, MASI AT, DECK- ER JL, MCCARTY DJ, YU T: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: ALTMAN R, ASCH E, BLOCH D et al.: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: CARMONA L, HERNANDEZ-GARCIA CH, VA- DILLO C et al.: Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: CUSH JJ, YAZICI H: Laboratory monitoring of biologic therapies. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S DAWSON JK, FEWINS HE, DESMOND J, LYNCH MP, GRAHAM DR: Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: SALAFFI F, CAROTTI M, BALDELLI S et al.: Subclinical interstitial lung involvement in rheumatic diseases. Correlation of high resolution computerized tomography and functional and cytologic findings. Radiol Med (Torino) 1999; 97: SARACOGLU M, NACIR B, INCEL NA, GENÇ H, ERDEM HR: Relationship between high resolution computed tomography findings and the Stoke index in patients with rheumatoid arthritis. Clin Rheumatol 2005; 24: BIEDERER J, SCHNABEL A, MUHLE C, GROSS WL, HELLER M, REUTER M: Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheu- 58
6 matoid arthritis. Eur Radiol 2004: 14; DE LEON DP, ACEVEDO-VASQUEZ E, SANCHEZ-TORRES A et al.: Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalance of tuberculosis. Ann Rheum Dis 2005; 64: WOLFE F, MICHAUD K, ANDERSON J, UR- BANSKY K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; A comparative study / İ.H. Köker et al. 50: SCHATZ P, PATTERSON R, KLONER R, FALK J: The prevalance of tuberculosis and positive tuberculin skin test in a steroid-treated asthmatic population. Ann Intern Med 1976; 84:
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT
INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
HRCT Versus Volume Rendering (Three Colors, Three Densities Lung Images) in Diagnosis of Small Airway Disease: A Comparative Study
Med. J. Cairo Univ., Vol. 84, No. 1, March: 359-364, 2016 www.medicaljournalofcairouniversity.net HRCT Versus Volume Rendering (Three Colors, Three Densities Lung Images) in Diagnosis of Small Airway Disease:
Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
Progress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
Silicosis in Turkish denim sandblasters
Occupational Medicine 2006;56:554 558 Published online 4 October 2006 doi:10.1093/occmed/kql094 Silicosis in Turkish denim sandblasters Metin Akgun 1, Arzu Mirici 1, Elif Yilmazel Ucar 1, Mecit Kantarci
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
A Radiologist s Approach
November 2003 Respiratory Symptoms in HIV+ Patients: A Radiologist s Approach MaryCatherine Arbour, Harvard Medical School Year III Pulmonary Manifestations of HIV Neoplasms Lung CA Lymphoma Kaposi s sarcoma
TNF-alpha antagonist therapy modify the tuberculin skin test response
DOI 10.1007/s00296-010-1424-3 ORIGINAL ARTICLE TNF-alpha antagonist therapy modify the tuberculin skin test response Tulin Cagatay Zeki Kilicaslan Penbe Cagatay Munevver Mertsoylu Ziya Gulbaran Reyhan
Outline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
Rheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
Pulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
10/17/2016. Nuts and Bolts of Thoracic Radiology. Objectives. Techniques
Nuts and Bolts of Thoracic Radiology October 20, 2016 Carleen Risaliti Objectives Understand the basics of chest radiograph Develop a system for interpreting chest radiographs Correctly identify thoracic
SIMPONI (GOLIMUMAB) ɇɉȼⱥ ȼɔɂɇɉɀɇɉɋɍ ȼ ɅȿɑȿɇɂȿɌɈ ɇⱥ ȼɔɂɉⱥʌɂɍȿʌɇɂɍȿ ɋɍⱥȼɇɂ ɁȺȻɈɅəȼȺɇɂə ɂ. ɒɟɣɬɚɧɨɜ, Ɋ. Ɋɚɲɤɨɜ ɢ ɐɜ. ɉɟɬɪɚɧɨɜɚ Ɋɟɡɸɦɟ Ʉɥɸɱɨɜɢ ɞɭɦɢ:
32 SIMPONI (GOLIMUMAB),. -., -,. TNF-, -. - ( ), ( ) ( ), -, -. TNF- Simponi (Golimumab),., Simponi (Golimumab) - TNF-,,, - - TNF-. : TNF-,,, - I. Sheytanov, R. Rashkov and Ts. Petranova. SIMPONI (GOLIMUMAB)
DIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis
CLINICAL AUDIT Clinical Medicine 2013, Vol 13, No 4: 362 6 Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis Helen R Mujakperuo, Richard D Thompson and
Diffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
Tuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
Key words: longitudinal; nonsmoking; pulmonary function; rheumatoid arthritis
A Longitudinal Study of Lung Function in Nonsmoking Patients With Rheumatoid Arthritis* Jonathan P. Fuld, MBChB; Martin K. Johnson, MBChB; Mark M. Cotton, MBBS; Roger Carter, PhD; Simon W. Watkin, MBChB;
DOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE?
DOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Pubdate: Tue, 14 Apr 2009 Source: Canadian Medical Association Journal (Canada) Copyright: 2009 Canadian Medical Association
ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
Cryptogenic Organizing Pneumonia: Serial High-Resolution CT Findings in 22 Patients
Cardiopulmonary Imaging Original Research Lee et al. High-Resolution CT of Cryptogenic Organizing Pneumonia Cardiopulmonary Imaging Original Research Ju Won Lee 1 Kyung Soo Lee 1 Ho Yun Lee 1 Man Pyo Chung
Key words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray
Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,
Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
GRANULOMATOUS AND VASCULITIC CONDITIONS
GRANULOMATOUS AND VASCULITIC CONDITIONS Alexandria 18-21 st April 2007 Andrew C. Swift University Hospital Aintree Liverpool Granulomatous and Vasculitic Conditions Heterogenous group of Chronic inflammatory
Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease
26 ORIGINAL ARTICLE Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease Liyakat Ali Gauri 1, Qadir Fatima 2, Sharanbasu Diggi 3, Asim
Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
C.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5
Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER
Combined Pulmonary Fibrosis and Emphysema - A Case Series
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. III (January. 2017), PP 15-19 www.iosrjournals.org Combined Pulmonary Fibrosis and Emphysema
MOLECULAR AND EPIDEMIOLOGICAL INVESTIGATIONS OF LUNG INVOLVEMENT IN VERY EARLY RHEUMATOID ARTHRITIS
From the Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden MOLECULAR AND EPIDEMIOLOGICAL INVESTIGATIONS OF LUNG INVOLVEMENT IN VERY EARLY RHEUMATOID ARTHRITIS Guðrún
Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study
Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study B. Hernández-Cruz 1, S. Ponce-de-León-Rosales 2, J. Sifuentes-Osornio 3, A. Ponce-de-León-Garduño
LEARNING OBJECTIVES:
Ankylosing Spondylitis: Keys to Early Diagnosis & Common Pitfalls Jason Kolfenbach, MD Assistant Professor, Division of Rheumatology University of Colorado Health Science Center LEARNING OBJECTIVES: 1.
Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?
Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? N.G. Papadopoulos, Y. Alamanos 1, P.V. Voulgari, E.K. Epagelis, N. Tsifetaki, A.A. Drosos
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
Dual Energy CT for Gout
Dual Energy CT for Gout Benjamin D. Levine, MD Associate Professor of Radiology Dept. of Radiological Sciences Musculoskeletal Section UCLA Health Deposition of monosodium urate crystals (MSU) in joints
HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
Assessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes
136 Bulletin of the Hospital for Joint Diseases 2014;72(2):136-41 Assessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes Advantages of Using RAPID3/MDHAQ in Routine Care
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
Introduction to Radiology for TB Nurses
Introduction to Radiology for TB Nurses Juzar Ali, MD; FRCP(C); FCCP May 4, 2018 Essential Skills for the TB Nurse Case Manager Little Rock, AR May 3 4, 2017 Juzar Ali, MD; FRCP(C); FCCP has the following
ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
WARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
Objective: To determine the sensitivity of bacteriologic studies in pediatric pulmonary tuberculosis.
Microbiology of Pediatric Primary Pulmonary Tuberculosis* José M. Merino, MD; Teresa Alvarez, MD; Manuel Marrero, MD; Sara Ansó, MD; Ana Elvira, MD; Gemma Iglesias, MD; and José B. González, MD Objective:
REFERRAL GUIDELINES: RHEUMATOLOGY
Outpatient Page 1 1 REFERRAL GUIDELINES: RHEUMATOLOGY Date of birth Demographic Contact details (including mobile phone) Clinical Reason for referral Duration of symptoms Essential Referral Content Referring
INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
PDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23314
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
e-figure 1. The design of the study.
e-figure 1. The design of the study. NDM, no diabetes; DM, diabetes; TB, tuberculosis; SN, sputum smear negative; SP, sputum smear positive; AFB, acid fast bacilli. e-figure 2. Representative H&E (A) and
Diagnostic and Complication Rate of Image-guided Lung Biopsies in Raigmore Hospital, Inverness: A Retrospective Re-audit
Page1 Original Article NJR 2011;1(1):1 7;Available online at www.nranepal.org Diagnostic and Complication Rate of Image-guided Lung Biopsies in Raigmore Hospital, Inverness: A Retrospective Re-audit S
Applications of PET/CT in Rheumatology. Role of PET/CT. Annibale Versari, MD Nuclear Medicine PET Center S.Maria Nuova Hospital Reggio Emilia Italy
CME Session Associazione Italiana di Medicina Nucleare ed Imaging Molecolare Applications of PET/CT in Rheumatology Role of PET/CT Annibale Versari, MD Nuclear Medicine PET Center S.Maria Nuova Hospital
Acute and Chronic Lung Disease
KATHOLIEKE UNIVERSITEIT LEUVEN Faculty of Medicine Acute and Chronic Lung Disease W De Wever, JA Verschakelen Department of Radiology, University Hospitals Leuven, Belgium Clinical utility of HRCT To detect
Tuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
Introduction ORIGINAL ARTICLE
Clin Rheumatol (2004) 23: 123 128 DOI 10.1007/s10067-003-0845-8 ORIGINAL ARTICLE Abdellah El Maghraoui Æ Souad Chaouir Æ Ahmed Abid Ahmed Bezza Æ Fatima Tabache Æ Lahsen Achemlal Ali Abouzahir Æ Driss
A RheuMetric physician checklist to quantitate levels of inflammation, damage and distress on 0 10 visual analogue scales
A RheuMetric physician checklist to quantitate levels of inflammation, damage and distress on 0 10 visual analogue scales I. Castrejón, J.R. Chua, T. Pincus Division of Rheumatology, Rush University Medical
UIP Possibile e Probabile
UIP Possibile e Probabile Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe - Milano Current definition of IPF IPF is a distinct type
Nontuberculous Mycobacterial Lung Disease
Non-TB Mycobacterial Disease Jeffrey P. Kanne, MD Nontuberculous Mycobacterial Lung Disease Jeffrey P. Kanne, M.D. Consultant Disclosures Perceptive Informatics Royalties (book author) Amirsys, Inc. Wolters
Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
CT Findings in the Elderly Lung
CT Findings in the Elderly Lung Poster No.: C-2498 Congress: ECR 2015 Type: Educational Exhibit Authors: P. Ananias, R. Coelho, H. M. R. Marques, O. Fernandes, M. Simões, L. Figueiredo; Lisbon/PT Keywords:
Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients ( )
Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004) M. Scheinberg 1, N. Hamerschlak 1, J.M. Kutner 1, A.A.F. Ribeiro 1, E. Ferreira 1, J. Goldenberg 1,2, M.H.
Hypothesis on the Evolution of Cavitary Lesions in Nontuberculous Mycobacterial Pulmonary Infection: Thin-Section CT and Histopathologic Correlation
CT of Nontuberculous Mycobacterial Pulmonary Infection Tae Sung Kim 1 Won-Jung Koh 2 Joungho Han 3 Myung Jin Chung 1 Ju Hyun Lee 1 Kyung Soo Lee 1 O Jung Kwon 2 Kim TS, Koh W-J, Han J, et al. Received
Quantitative CT in Chronic Obstructive Pulmonary Disease: Inspiratory and Expiratory Assessment
Cardiopulmonary Imaging Original Research kira et al. CT of Chronic Obstructive Pulmonary Disease Cardiopulmonary Imaging Original Research Masanori kira 1 Kazushige Toyokawa 1 Yoshikazu Inoue 2 Toru rai
Epidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
Judith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD
Pulmonary Cryptococcosis in Patients Without HIV Infection* Judith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD Purpose: To further elucidate the diagnostic and therapeutic approaches
DRUG INDUCED LUNG DISEASES
DRUG INDUCED LUNG DISEASES CHEMOTHERAPEUTIC AGENTS 1. CYTOTOXIC ANTIBIOTICS 2. ALKYLATING AGENTS 3. ANTIMETABOLITES 4. BIOLOGIC RESPONSE MODIFIERS CYTOTXIC ANTIBIOTICS BLEOMYCIN 1.CHRONIC PNEUMONITIS/
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun. 26.11.11 Introduction Interstitial Lung Diseases (ILD) are group of diseases that affect the interstitium of the lungs,
APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
APPLICANT (stamp sticker acceptable) Page 1 Fm SA1620 Etanercept INITIAL APPLICATION - juvenile idiopathic arthritis Applications only from a named specialist rheumatologist. Approvals valid f 6 months.
Infliximab Drug information. Infliximab can treat rheumatoid arthritis and psoriatic arthritis.
Infliximab Drug information Infliximab can treat rheumatoid arthritis and psoriatic arthritis. Infliximab should effectively treat your condition, and stop it causing damage to your joints. It has been
Idiopathic pulmonary fibrosis (IPF) is a
Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease
Rheumatology 2002;41:1268 1272 Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease H. Ihn, Y. Asano, M.
Respiratory Interactive Session. Elaine Borg
Respiratory Interactive Session Elaine Borg Case 1 Respiratory Cytology 55 year old gentleman Anterior mediastinal mass EBUS FNA Case 1 Respiratory Cytology 55 year old gentleman with anterior mediastinal
Chapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
Announcing HUMIRA. Psoriasis Starter Package
Announcing HUMIRA (adalimumab) Psoriasis Starter Package HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy
High-Resolution CT of the Lung: Patterns of Disease and Differential Diagnoses
Radiol Clin N Am 43 (2005) 513 542 High-Resolution CT of the Lung: Patterns of Disease and Differential Diagnoses Michael B. Gotway, MD a, *, Gautham P. Reddy, MD, MPH b, W. Richard Webb, MD b, Brett M.
Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
ORIGINAL ARTICLE 2017 Mar 13. [Epub ahead of print] Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
G. Poór for the Leflunomide Multinational Study Group and V. Strand 1
Rheumatology 2004;43:744 749 Advance Access publication 16 March 2004 Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind,
Opinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)
Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital
ORIGINAL ARTICLE Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital ARM Fauzi, MRCP Kulliyah of Medicine, International Islamic
Understanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H. Kautiainen 3, M. Leirisalo-Repo 1
Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H.
Cardiology Division, Hospital Universitario Lucus Augusti, c/ulises Romero 1, Lugo, Spain 2
Mediators of Inflammation Volume 2012, Article ID 674265, 8 pages doi:10.1155/2012/674265 Clinical Study Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function
Adult-onset Still s disease a polygenic autoinflammatory disease
Adult-onset Still s disease a polygenic autoinflammatory disease Tom Pettersson, MD, PhD University of Helsinki and Helsinki University Central Hospital IL-1 mediated diseases past present and future Såstaholm
Pulmonary Hypertension in Patients With Bronchiectasis: Prognostic Significance of CT Signs
Cardiopulmonary Imaging Original Research Devaraj et al. CT of Pulmonary Hypertension Cardiopulmonary Imaging Original Research Anand Devaraj 1,2 Athol U. Wells 3 Mark G. Meister 1 Michael R. Loebinger
Sample Case Study. The patient was a 77-year-old female who arrived to the emergency room on
Sample Case Study The patient was a 77-year-old female who arrived to the emergency room on February 25 th with a chief complaint of shortness of breath and a deteriorating pulmonary status along with
Bronchial involvement in chronic eosinophilic pneumonia: a case report
Case Report Bronchial involvement in chronic eosinophilic pneumonia: a case report Na Hee Kim 1, Kyung Hee Lee 1, Jun Ho Kim 1, Jae Hwa Cho 2, Lucia Kim 3, Eugene Kim 1 1 Department of Radiology, Inha
Interesting Cases. Pulmonary
Interesting Cases Pulmonary 54M with prior history of COPD, hep B/C, and possible history of TB presented with acute on chronic dyspnea, and productive cough Hazy opacity overlying the left hemithorax
Isoniazid Preventive Therapy (IPT)
Isoniazid Preventive Therapy (IPT) Josefina Cadorna-Carlos, M.D. Professor of Pediatrics U E R M M M C Objectives 1. Define IPT. 2. Discuss the indications for IPT. 3. Present RCT s for IPT (6H vs 9H).
Specific Basic Standards for Osteopathic Fellowship Training in Pulmonary / Critical Care Medicine
Specific Basic Standards for Osteopathic Fellowship Training in Pulmonary / Critical Care Medicine American Osteopathic Association and American College of Osteopathic Internists BOT Rev. 2/2011 These
Diagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
Infliximab and questionable efficacy of recommendations on tuberculosis screening
Infliximab and questionable efficacy of recommendations on tuberculosis screening Introduction Infliximab (Remicade ) is a TN-alpha blocker, indicated for severe rheumatoid arthritis, Crohn's disease,
HUMIRA (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection,
CLINICAL COURSE AND REMISSION RATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RELATIONSHIP TO OUTCOME AFTER 5 YEARS
British Journal of Rheumatology 1998;37:1324 1329 CLINICAL COURSE AND REMISSION RATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RELATIONSHIP TO OUTCOME AFTER 5 YEARS K. EBERHARDT and E. FEX* Department
Idiopathic Pulmonary Fibrosis: Spectrum of High-Resolution CT Findings
Idiopathic Pulmonary Fibrosis on CT Chest Imaging Pictorial Essay Carolina lthoff Souza 1 Nestor L. Müller 1 Julia Flint 2 Joanne L. Wright 2 ndrew Churg 2 Souza C, Müller NL, Flint J, Wright JL, Churg